| 张晓月,刘 芳,秦 虹.克唑替尼治疗ALK重排NSCLC耐药后的进展模式以及局部治疗的应用价值[J].肿瘤学杂志,2019,25(9):830-835. |
| 克唑替尼治疗ALK重排NSCLC耐药后的进展模式以及局部治疗的应用价值 |
| Continuing Crizotinib Therapy or Combined with Local Therapy for Disease Progression Model in ALK Rearrangement NSCLC After Drug Resistance |
| 投稿时间：2018-11-02 |
| DOI：10.11735/j.issn.1671-170X.2019.09.B014 |
|
 |
| 中文关键词: 间变性淋巴瘤激酶 克唑替尼 寡进展 脑转移 局部治疗 |
| 英文关键词:anaplastic lymphoma kinase crizotinib oligoprogression brain metastases local therapy |
| 基金项目:重庆市基础与前沿研究计划项目（cstc2015jcyjBX0084） |
|
| 摘要点击次数: 1482 |
| 全文下载次数: 424 |
| 中文摘要: |
| 摘 要：间变性淋巴瘤激酶基因重排的非小细胞肺癌是肺癌的一种特定的分子亚型。克唑替尼耐药后疾病进展主要以寡进展为主，脑转移最常见。继续使用克唑替尼或联合局部治疗能够带来获益。全文将从临床研究和真实世界的研究介绍克唑替尼耐药后的疾病进展的特征和克唑替尼继续使用的疗效，并分析联合局部治疗的应用价值以及目前尚未解决的问题。 |
| 英文摘要: |
| Abstract：Anaplastic lymphoma kinase(ALK) gene rearrangement defines a new molecular subtype of non-small-cell lung cancer(NSCLC). Crizotinib is an oral ALK-tyrosine kinase inhibitor and it has significant antitumor activity. Oligoprogression is the main model and brain metastasis is the most common after crizotinib resistance. Local therapy could extend disease control with crizotinib in oligoprogressive disease and continuing crizotinib beyond progression diease(CBPD) might favorably impact survival outcomes. In the review，we will analyze the disease progression model and the efficacy of CBPD in ALK rearrangement NSCLC from the data of reported clinical trials and real-world studies. The application value of local therapy，as well as the unsolved problem in combined crizotinib with local therapy will be discussed. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |